Stock comparison
Mettler-Toledo International
Pfizer
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
MTD
Mettler-Toledo International
Market cap
$22.29B
Sector
Healthcare
PFE
Pfizer
Market cap
$147.62B
Sector
Healthcare
Overall winner
Mettler-Toledo International MTD
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | MTD | PFE | Winner |
|---|---|---|---|
| Warren Buffett | 69B | 55C | MTD |
| Benjamin Graham | 65B | 53C | MTD |
| Philip Fisher | 63C | 47D | MTD |
| Peter Lynch | 66B | 22F | MTD |
| Joel Greenblatt | 68B | 31F | MTD |
| Charlie Munger | 74B | 58D | MTD |
| Terry Smith | 70B | 54D | MTD |
Side-by-side metrics
| Metric | MTD | PFE |
|---|---|---|
| Market cap | $22.29B | $147.62B |
| P/E (TTM) | 25.3x | 19.2x |
| EV/EBIT | 21.6x | 13.4x |
| ROIC (TTM) | 36.09% | 7.97% |
| Gross margin | 57.79% | 69.35% |
| Net margin | 21.4% | 11.83% |
| Revenue CAGR 5y | 2.01% | -6.33% |
| EPS CAGR 5y | 6.12% | -23.42% |
| Debt / Equity | - | 0.7x |
| Dividend yield | 0.0% | 6.79% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
MTD leads on
- Revenue CAGR 5y2.01%vs -6.33%+132%
- EPS CAGR 5y6.12%vs -23.42%+126%
- Debt / Equity-vs 0.7x+101%
- ROIC (TTM)36.09%vs 7.97%+78%
PFE leads on
- Dividend yield6.79%vs 0.0%+100%
- Market cap$147.62Bvs $22.29B+85%
- EV/EBIT13.4xvs 21.6x+38%
- P/E (TTM)19.2xvs 25.3x+24%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.